Abstract
Molecularly targeted medicine poses substantial challenges for incorporation into the existing U.S. health care system. It is argued here that performance-based risk-sharing arrangements may be a promising approach to address the competing needs of patients, clinicians, and payers.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Genome, Human
-
Genomics / economics
-
Genomics / methods
-
Humans
-
Models, Economic*
-
Neoplasms / economics
-
Neoplasms / genetics*
-
Neoplasms / therapy*
-
Reimbursement, Incentive*
-
Risk Sharing, Financial*
-
United States